Allarity Therapeutics Q2 FY26 net loss widens to $3.41 million; comprehensive loss narrows to $3.67 million
Reuters2026/08/14 12:01- Allarity Therapeutics posted a Q2 net loss of USD 3.41 million, widening from USD 2.32 million a year earlier; loss per share rose to USD 0.21.
- Operating loss narrowed to USD 2.67 million from USD 4.13 million, as R&D fell 42% to USD 1.35 million and G&A dropped 26.82% to USD 1.33 million.
- Cash and restricted cash climbed to USD 26.9 million at June 30, up from USD 14.7 million a year earlier; operating cash outflow was USD 2.6 million.
- Completed a Phase 3-ready stenoparib API manufacturing campaign in July, with all payments booked as prepaid expenses and no additional cash outlays expected.
- USPTO granted a U.S. patent covering the stenoparib DRP companion diagnostic through April 2042; CLIA certification secured for its in-house DRP testing lab.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI remains above $83.50 as Iran fires missiles following US strikes
Oil jumps more than 2% after US attack on Iran's Larak island
Itochu says no decision yet on reported Dentsu Soken tender offer
After Waller's hawkish speech, the market focuses on "rate hikes", but Morgan Stanley says balance sheet reduction is more likely.
After the Jackson Hole meeting, the market's focus has shifted to interest rate hike expectations. However, Morgan Stanley economist Carpenter pointed out that Walsh's long-standing stance on reducing the $7 trillion balance sheet should not be overlooked. It is expected that the Federal Reserve may begin a balance sheet reduction of more than $1.5 trillion next year, partially replacing rate hikes.
Crypto prices
More
